Sector News

Axovant stock jumps as Medivation founder takes CEO post

April 11, 2017
Life sciences

Axovant Sciences has appointed Medivation founder David Hung, M.D., as CEO. The news sparked a 30% surge in Axovant’s share price as investors cheered the potential implications of the man who led Medivation to a $14 billion buyout taking charge of the Alzheimer’s hopeful.

Hung bowed out as CEO of Medivation after 13 years by engineering one final deal in September: A $14 billion takeover by Pfizer. That deal left Hung $354 million better off, before taxes, and catapulted him toward the top of the list of the most eligible unattached biotech execs. Axovant, an Alzheimer’s player, has pulled off a coup by securing Hung’s services, along with another member of the Medivation management team.

Investors responded to the coup by driving the share price of Axovant up 30%, a considerable feat for a company with a market cap now touching $2 billion.

The surge is, in part, a reflection of the credibility Hung and fellow new arrival Marion McCourt—the former COO of Medivation—bring to the Axovant. The company usually gets a double dose of skepticism because of its chosen therapeutic field and its jaw dropping rise from nowhere to a $315 million IPO.

With Axovant having set its course toward clinical data under the leadership of founder Vivek Ramaswamy, it is questionable how much Hung can influence whether the company succeeds. But the fact that a man with his pick of roles chose Axovant paints it and its prospects in a good light.

The snag in that rosy interpretation of Hung’s arrival is that his reputation is built on success in cancer, not Alzheimer’s. Hung’s track record in Alzheimer’s is blemished.

Medivation began life by picking up Dimebon from Russian researchers and went on to strike a $725 million pact with Pfizer. That unraveled when clinical trial data came up short.

Now, Hung gets another crack at the toughest of indications.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”